What is known about birth-defect risk following erythromycin stearate exposure in early pregnancy?

Evidence for erythromycin stearate is conflicting: most studies suggest no association with major birth defects, but limited epidemiological evidence suggests a small increased risk, particularly cardiovascular malformations, after first-trimester exposure.